- Report
- October 2023
- 77 Pages
India
From €3358EUR$3,500USD£2,892GBP
- Report
- June 2019
- 15 Pages
Global
- Report
- May 2024
- 200 Pages
From €3982EUR$4,150USD£3,430GBP
- Report
- October 2022
- 103 Pages
North America
From €1439EUR$1,500USD£1,240GBP
- Webinar
- September 2022
- 4 Hours
Global
From €942EUR$982USD£811GBP
- Report
- November 2019
- 82 Pages
Global
From €3118EUR$3,250USD£2,686GBP
- Webinar
- August 2019
- 90 Minutes
Global
- Journal
- May 2024
- 46 Pages
Global
From €408EUR$425USD£351GBP
- Report
- November 2021
- 365 Pages
Global
From €3358EUR$3,500USD£2,892GBP
- Report
- November 2021
- 213 Pages
Global
From €2878EUR$3,000USD£2,479GBP
- Report
- February 2023
- 292 Pages
Global
From €3425EUR$3,570USD£2,950GBP
- Book
- February 2024
- 928 Pages
- Book
- March 2023
- 1056 Pages
- Book
- November 2022
- 400 Pages
- Book
- November 2022
- 480 Pages
- Book
- April 2022
- 480 Pages
- Book
- April 2022
- 576 Pages
- Book
- December 2021
- 624 Pages
- Book
- September 2021
- 464 Pages
The Drug Metabolism market within the context of Biotechnology is a rapidly growing sector, with a focus on the development of new drugs and treatments. It involves the study of how drugs are broken down and metabolized in the body, and how this affects their efficacy and safety. This market is driven by the need for more effective and safer drugs, as well as the increasing demand for personalized medicine. Companies in this market are developing new technologies to improve drug metabolism, such as artificial intelligence and machine learning. They are also exploring new ways to identify and target drug metabolism pathways, as well as developing new drug delivery systems.
Some companies in the Drug Metabolism market include AbbVie, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more